If a new drug were discovered that reduced cardiovascular events by 20–30%, improved insulin sensitivity, lowered blood pressure, enhanced immune function, and improved cognitive performance — with no side effects — it would be the biggest medical story of the decade. That drug already exists. It's called sleep.
Despite overwhelming evidence that sleep quality and duration are independent cardiovascular risk factors, most physicians spend approximately zero seconds asking about sleep during an annual physical. This is one of the most consequential blind spots in preventive medicine.
The evidence
Sleep duration follows a U-shaped curve for cardiovascular risk. Both too little and too much sleep are associated with worse outcomes, but the risks of insufficient sleep are far more common and better documented.
A meta-analysis of 15 prospective studies covering over 470,000 participants found that people sleeping less than 6 hours per night had a 48% increased risk of developing coronary heart disease and a 15% greater risk of stroke, compared to those sleeping 7–8 hours.
But duration is only part of the story. Sleep quality — fragmentation, sleep-disordered breathing (especially obstructive sleep apnea), and circadian disruption — may matter even more.
Sleep apnea: the hidden epidemic
Obstructive sleep apnea (OSA) is estimated to affect 15–30% of men and 10–15% of women. In people with metabolic syndrome, the prevalence is even higher — possibly above 50%. Most cases are undiagnosed.
OSA is not just snoring. It's repeated episodes of airway collapse during sleep, each causing a surge of adrenaline, a spike in blood pressure, and a drop in blood oxygen. Over months and years, this nightly stress response drives hypertension, atrial fibrillation, heart failure, and stroke.
The challenge is that most people with OSA don't know they have it. They may feel tired during the day, but they attribute it to stress or aging. Their bed partner may notice loud snoring or pauses in breathing, but many people sleep alone. Without asking about sleep — specifically, about snoring, daytime fatigue, and observed apneas — the condition remains invisible.
What we do at Health Detectors
Our pre-arrival digital intake includes a structured sleep assessment: the STOP-Bang questionnaire (a validated OSA screening tool), sleep duration, quality, and patterns. If the score suggests moderate-to-high OSA risk, we flag it for the Quarterback Physician before the patient arrives in Munich.
On Day 1, the physician integrates sleep assessment findings with the clinical examination. Neck circumference, BMI, blood pressure pattern, and HbA1c all provide additional context. If OSA is suspected, we can arrange a home sleep study or refer for polysomnography.
Why this matters for executives specifically
High-performing professionals are disproportionately affected by sleep problems — irregular schedules, frequent travel across time zones, high stress, and a culture that treats sleep deprivation as a badge of honor. If you're flying from the US to Munich for a health assessment, there's a very good chance your sleep could use clinical attention. We make sure it gets it.
The closing risk report includes specific sleep recommendations when relevant — not generic "sleep hygiene" tips, but targeted guidance based on your actual risk profile. For patients with suspected OSA, this includes referral pathways for diagnosis and treatment (CPAP, oral appliances, or surgical options depending on severity).
References
- Cappuccio FP, et al. Sleep duration and all-cause mortality: a systematic review and meta-analysis. Sleep. 2010;33(5):585-592.
- Benjafield AV, et al. Estimation of the global prevalence of obstructive sleep apnea. Lancet Respir Med. 2019;7(8):687-698.
- Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841-858.